HK1183863A1 - Compounds for preparing immunological adjuvant - Google Patents

Compounds for preparing immunological adjuvant

Info

Publication number
HK1183863A1
HK1183863A1 HK13111246.4A HK13111246A HK1183863A1 HK 1183863 A1 HK1183863 A1 HK 1183863A1 HK 13111246 A HK13111246 A HK 13111246A HK 1183863 A1 HK1183863 A1 HK 1183863A1
Authority
HK
Hong Kong
Prior art keywords
compounds
immunological adjuvant
preparing immunological
preparing
adjuvant
Prior art date
Application number
HK13111246.4A
Other languages
English (en)
Chinese (zh)
Inventor
弗朗西斯．
．方
詹姆斯．
．福伊
林恩．霍金斯
查爾斯．萊梅林
安德魯．萊斯卡博
牛翔
吳闊明
Original Assignee
衛材 管理有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 衛材 管理有限公司 filed Critical 衛材 管理有限公司
Publication of HK1183863A1 publication Critical patent/HK1183863A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids
    • C07F9/1411—Esters of phosphorous acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK13111246.4A 2005-06-30 2013-10-03 Compounds for preparing immunological adjuvant HK1183863A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69532405P 2005-06-30 2005-06-30

Publications (1)

Publication Number Publication Date
HK1183863A1 true HK1183863A1 (en) 2014-01-10

Family

ID=37192315

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13111246.4A HK1183863A1 (en) 2005-06-30 2013-10-03 Compounds for preparing immunological adjuvant

Country Status (10)

Country Link
US (5) US7683200B2 (fr)
EP (3) EP2292628A3 (fr)
JP (3) JP5214446B2 (fr)
KR (1) KR101294455B1 (fr)
CN (3) CN101213199B (fr)
AU (1) AU2006265986B2 (fr)
CA (1) CA2611721C (fr)
HK (1) HK1183863A1 (fr)
IL (3) IL187819A (fr)
WO (1) WO2007005583A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
CN101213199B (zh) 2005-06-30 2013-12-18 卫材R&D管理有限公司 用于制备免疫佐剂的化合物
EP2240435B1 (fr) * 2007-12-18 2012-08-01 Eisai R&D Management Co., Ltd. Reactifs et procedes pour la synthese de beta-ceto amide d'un precurseur synthetique de l'adjuvant immunologique e6020
CA2784447A1 (fr) 2009-12-22 2011-06-30 Sanofi Pasteur Limited Compositions immunogeniques adjuvantes et methodes associees
WO2012042003A1 (fr) * 2010-09-30 2012-04-05 Eurocine Vaccines Ab Compositions améliorées de vaccin
US9327021B2 (en) 2010-11-15 2016-05-03 Sanofi Pasteur Limited Immunogenic compositions
MX2013006255A (es) 2010-12-03 2015-08-05 Sanofi Pasteur Ltd Composicion para inmunizacion contra streptococcus pneumoniae.
WO2013184900A2 (fr) 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Compositions immunogènes et procédés associés
JP2015533366A (ja) * 2012-10-19 2015-11-24 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 改良されたヒトヘルペスウイルス免疫療法
EP2912045A4 (fr) 2012-10-29 2016-07-13 Molecular Transfer Inc Phospholipides méthyliques polycationiques pour une libération améliorée d'acides nucléiques dans des cellules eucaryotes
EP2742952A1 (fr) 2012-12-17 2014-06-18 Eurocine Vaccines AB Composition vaccinale
EP2958889B1 (fr) 2013-02-25 2017-03-22 The Scripps Research Institute Néoseptines : petits adjuvants moléculaires
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US10772946B2 (en) 2015-10-13 2020-09-15 Sanofi Pasteur Immunogenic compositions against S. aureus
WO2017137085A1 (fr) 2016-02-11 2017-08-17 Sanofi Pasteur Vaccins contre la méningite comprenant des subtilinases
KR20230034936A (ko) * 2020-04-06 2023-03-10 에자이 알앤드디 매니지먼트 가부시키가이샤 면역 반응을 생성하는 백신, 아쥬반트 및 방법
WO2022090359A1 (fr) 2020-10-28 2022-05-05 Sanofi Pasteur Liposomes contenant un agoniste du tlr4, leur préparation et leurs utilisations
WO2023056089A1 (fr) 2021-10-03 2023-04-06 Eisai R&D Management Co., Ltd. Formulations d'adjuvants immunologiques comprenant un agoniste du tlr4 e6020

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004672A1 (fr) * 1991-09-11 1993-03-18 Pitman-Moore, Inc. Procede de renforcement du systeme immunitaire d'un hote a l'aide de polypeptides encapsules dans des liposomes
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6835721B2 (en) * 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
PT1147117E (pt) * 1999-02-01 2004-10-29 Eisai Co Ltd Compostos adjuvantes imunologicos
WO2000067788A2 (fr) * 1999-05-06 2000-11-16 Genetics Institute, Inc. Emploi de molecules de co-stimulation solubles favorisant les reponses immunitaires
EP1307466B1 (fr) * 2000-07-31 2005-11-16 Eisai Co., Ltd. Composants et compositions d'adjuvants immunologiques et procedes d'utilisation de ceux-ci
JP4176021B2 (ja) * 2002-03-05 2008-11-05 セルメディシン株式会社 固体化組織免疫アジュバント
CN1535726A (zh) * 2003-04-11 2004-10-13 上海欣安基因免疫与疫苗研究开发有限 一种分子佐剂、其制备方法以及含该分子佐剂的基因疫苗
CN101213199B (zh) 2005-06-30 2013-12-18 卫材R&D管理有限公司 用于制备免疫佐剂的化合物

Also Published As

Publication number Publication date
US20100197951A1 (en) 2010-08-05
EP3138844B1 (fr) 2018-05-02
EP2292628A2 (fr) 2011-03-09
EP3138844A1 (fr) 2017-03-08
JP5214446B2 (ja) 2013-06-19
CN103012304A (zh) 2013-04-03
CA2611721A1 (fr) 2007-01-11
AU2006265986A1 (en) 2007-01-11
US8962857B2 (en) 2015-02-24
CN101213199B (zh) 2013-12-18
IL213174A0 (en) 2011-07-31
IL213173A0 (en) 2011-07-31
US20140323739A1 (en) 2014-10-30
AU2006265986B2 (en) 2012-02-23
US20120232298A1 (en) 2012-09-13
US20070082875A1 (en) 2007-04-12
US20140012011A1 (en) 2014-01-09
IL213174A (en) 2012-10-31
JP2009502742A (ja) 2009-01-29
KR20080031350A (ko) 2008-04-08
EP2292628A3 (fr) 2011-05-11
IL187819A0 (en) 2008-08-07
US8519170B2 (en) 2013-08-27
CA2611721C (fr) 2014-04-22
KR101294455B1 (ko) 2013-08-07
CN103012304B (zh) 2014-07-23
JP5923373B2 (ja) 2016-05-24
CN103012169B (zh) 2016-04-20
CN101213199A (zh) 2008-07-02
EP1910387A1 (fr) 2008-04-16
IL187819A (en) 2012-04-30
CN103012169A (zh) 2013-04-03
JP2012162562A (ja) 2012-08-30
JP2015051978A (ja) 2015-03-19
US8198474B2 (en) 2012-06-12
WO2007005583A1 (fr) 2007-01-11
EP1910387B1 (fr) 2016-11-16
US7683200B2 (en) 2010-03-23
US8754236B2 (en) 2014-06-17

Similar Documents

Publication Publication Date Title
HK1183863A1 (en) Compounds for preparing immunological adjuvant
ZA200710558B (en) Immunogens for meningitidis-a vaccines
HK1118477A1 (en) Immunogenic composition comprising an adjuvant
GB0605521D0 (en) Adjuvant
EP1850870A4 (fr) Composition destinee a un adjuvant contenant l'acide poly-gamma-glutamique
AP2007004171A0 (en) Novel compounds
GB0512751D0 (en) New adjuvant
EP1868612A4 (fr) Nouveaux composes
IL178001A0 (en) Process for preparing 5-methyl-2-furfural
EP1868611A4 (fr) Nouveaux composes
TWI372145B (en) Process for preparing alkylanilides
EP1858530A4 (fr) Composes polyphosphazene immunostimulants
GB2442408B (en) Mycobacterium W as an adjuvant
TWI365869B (en) Process for the preparation of phenol
EP2221062A4 (fr) Nouvel adjuvant
EP1869026A4 (fr) Composes innovants
IL189574A0 (en) Process for preparing 1-substituted-5-acylimidazole compounds
GB0500140D0 (en) Novel compounds
GB0507672D0 (en) Adjuvant
EP1884987A4 (fr) Procede de production d' un compose a base de silicium
IL183804A0 (en) Process for preparing substituted 2-alkoxycarbonyl-3-aminothiophenes
GB0406749D0 (en) Novel adjuvant
AP2007004280A0 (en) Immunological adjuvant emulsion
GB0619814D0 (en) Interferon alpha-14 for use as an immunological adjuvant
GB0712691D0 (en) Interferon-alpha 1 for use as an immunological adjuvant